



Controlled Substances Schedule II Authority

Course Description and Objectives

The following information will help to ensure the participants of your program will be eligible for CS II furnishing privileges in California as required by the Board of Registered Nursing and the Drug Enforcement Agency.

Course Description

A *three-hour* course focusing on the principles of pharmacology that serves as a foundation for the pharmacotherapeutic management of patients evaluated and treated for conditions with Schedule II Controlled Substances by advanced practice nurses. Issues related to legal requirements for furnishing Schedule II Controlled Substances are highlighted.

Course Objectives: Specialty Content (Speaker Responsibility)

1. Identify the relationship of the natural history of disease or condition, pathophysiology, and symptomatology to pharmacotherapeutic agents commonly used to treat patients with conditions requiring the use of CS II medications related to specialty practice.
2. Discuss the pharmacokinetic and pharmacodynamic principals of CS II medications commonly used in the diagnosis, prevention, and treatment of healthcare conditions affecting patients across the lifespan.
3. Describe ethical and legal standards and ramifications of prescribing controlled substances.

****Participants must also complete a course module related to regulatory requirements.***

Course Objectives: Regulatory Content (CANP's Responsibility)

1. Discuss state and federal regulations pertaining to furnishing, dispensing, and administering controlled substances schedule II through V medication by nurse practitioners.
2. Discuss the relationship of the nurse practitioner's education, experience, and competence to furnish controlled substances schedule II through V.
3. Identify components necessary for proper techniques of prescription writing for CS II through V medications consistent with the Health and Safety and Pharmacy laws.
4. Outline required components of a furnishing standardized procedure or protocol for CS II and III controlled substance medications in a patient-specific protocol in accord with Business and Professions Code, Section 2836.1.